Very interesting news I would of thought before their latest purchase and potential future outlay that they may have considered a T/O of OCC would of been a lot cheaper… Shows that either they are blind or unaware of OCC in the mkt which I find hard to believe with OCC’s latest deal in the USA…
Going by the Company’s above acquisition of Embody Inc Paul Anderson talk of a Significant Re-rate is only a matter of time and we should be $1 plus by all accounts going from what Zimmer Biometric paid for its latest acquisition……
Stem Cell Therapy advancements, page-383
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $130.7M | |||
| Open | High | Low | Value | Volume |
| 62.0¢ | 64.0¢ | 61.5¢ | $693.0K | 1.108M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9261 | 62.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 63.0¢ | 29093 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |